AXSM - Axsome Therapeutics Inc.

-

$undefined

N/A

(N/A)

Axsome Therapeutics Inc. NASDAQ:AXSM Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders for which there are limited treatment options. For the many people facing unsatisfactory treatments for CNS disorders, Axsome accelerates the invention and adoption of life-changing medicines. Axsome's core CNS product candidate portfolio includes five clinical-stage candidates, AXS-05, AXS-07, AXS-09, AXS-12, and AXS-14. AXS-05 is being developed for major depressive disorder (MDD), Alzheimer's disease (AD) agitation, and as a treatment for smoking cessation. AXS-07 is being developed for the acute treatment of migraine. AXS-12 is being developed for the treatment of narcolepsy. AXS-14 is being developed for fibromyalgia. AXS-05, AXS-07, AXS-09, AXS-12, and AXS-14 are investigational drug products not approved by the FDA.

Location: 22 Cortlandt Street, 16Th Floor, New York, 10007, US | Website: www.axsome.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

4.213B

Cash

315.7M

Avg Qtr Burn

-41.87M

Short % of Float

21.01%

Insider Ownership

16.84%

Institutional Own.

86.06%

Qtr Updated

06/30/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Approved

Quarterly sales

Sunosi® (solriamfetol) Details
Mental health, Excessive daytime sleepiness

Approved

Quarterly sales

PDUFA

Approval decision

NDA

Submission

Solriamfetol Details
Shift work disorder

Phase 3

Data readout

Solriamfetol Details
Major depressive disorder

Phase 3

Data readout

Solriamfetol Details
Binge eating disorder

Phase 3

Data readout

Phase 3

Data readout

Solriamfetol Details
Attention deficit hyperactivity disorder

Phase 3

Data readout

AXS-05 (NMDA receptor antagonist & sigma-1 agonist) Details
Alzheimer's disease

Big Mover™

Susp. Mover™

Phase 3

Data readout

AXS-05 (NMDA receptor antagonist & sigma-1 agonist) Details
Alzheimer's disease

Big Mover™

Susp. Mover™

Phase 3

Data readout

Phase 2/3

Initiation